Journal of Commercial Biotechnology

Editorial: Is the UK NHS a good place to do clinical trials?
pp. 205-207(3)
Author: Steiner, Jan

Introduction to the debate: How much regulation do we want or need?
pp. 208-208(1)
Author: Burke, Derek

NGO war on biotechnology
pp. 209-222(14)
Authors: Miller, Henry I; Conko, Gregory

Plant biotechnology, the regulator and the consumer
pp. 222-227(6)
Author: Bainbridge, Janet

The latest orphan drug designations and the Commission Communication on Regulation (EC) 141/2000
pp. 228-238(11)
Author: Shah, Rashmi R

Corporate development in biotechnology in 2005
pp. 239-248(10)
Author: Williams, Alan

Distribution of data and unique material resources made with NIH funding
pp. 249-262(14)
Author: Rohrbaugh, Mark L

Amgen v TKT: Assessment of inventive concept is crucial for assessing infringement of biotechnology patents
pp. 263-270(8)
Author: Cook, William

The quest for generic biotechnology pharmaceuticals in the USA
pp. 271-274(4)
Authors: Kowalski, Thomas J; Fekete, Pamela; Yvon, Anne-Marie C

The DNA/RNA market to 2010
pp. 275-278(4)
Authors: Belsey, Mark; Pavlou, Alex K

Legal and regulatory update
pp. 279-288(10)
Authors: Wilkinson, John; Dorey, Frederick J

Financial accounts reports
pp. 289-291(3)
Author: Aaronson, Colin